Literature DB >> 19294534

Antioxidants but not doxycycline treatments restore depressed beta-adrenergic responses of the heart in diabetic rats.

Ayca Bilginoglu1, Aytac Seymen, Erkan Tuncay, Esma Zeydanli, Aslihan Aydemir-Koksoy, Belma Turan.   

Abstract

Reactive oxygen species (ROS) play important roles in the development of diabetic cardiomyopathy. Matrix metalloproteinases (MMPs) can get activated by ROS and contribute to loss of myocardial contractile function in oxidative stress injury. Previously we have shown that either a MMP-2 inhibitor doxycycline or an antioxidant selenium treatment in vivo prevented diabetes-induced cardiac dysfunction significantly. In addition, there is an evidence for impaired cardiac responsiveness to beta-adrenoceptor (beta AR) stimulation in experimental animals with diabetes. The exact nature of linkage between the functional depression in cardiac responses to catecholamines and the variations in uncoupling of beta AR in diabetes has not been clearly defined. Therefore, we aimed to evaluate the effect of in vivo administration of doxycycline on beta AR responses of isolated hearts from diabetic rats and compare these data with two well-known antioxidants; sodium selenate and (n-3) fatty acid-treated diabetic rats. We examined the changes in the basal cardiac function in response to the beta AR stimulation, adenylate cyclase activity, and beta AR affinity to its agonist, isoproterenol. These results showed that antioxidant treatment of diabetic rats could protect the hearts against diabetes-induced depression in beta AR responses, significantly while doxycycline did not have any significant beneficial action on these parameters. As a summary, present data, in part, demonstrate that antioxidants and MMP inhibitors could both regulate MMP function but may also utilize different mechanisms of action in cardiomyocytes, particularly related with beta AR signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19294534     DOI: 10.1007/s12012-009-9032-8

Source DB:  PubMed          Journal:  Cardiovasc Toxicol        ISSN: 1530-7905            Impact factor:   3.231


  7 in total

1.  Sildenafil and FDP-Sr attenuate diabetic cardiomyopathy by suppressing abnormal expression of myocardial CASQ2, FKBP12.6, and SERCA2a in rats.

Authors:  Yu-si Cheng; De-zai Dai; Hui Ji; Qi Zhang; Yin Dai
Journal:  Acta Pharmacol Sin       Date:  2011-03-28       Impact factor: 6.150

2.  Cardioprotective effect of propranolol on diabetes-induced altered intracellular Ca2+ signaling in rat.

Authors:  Erkan Tuncay; Esma N Zeydanli; Belma Turan
Journal:  J Bioenerg Biomembr       Date:  2011-11-30       Impact factor: 2.945

3.  Attenuation of beta2-adrenergic receptors and homocysteine metabolic enzymes cause diabetic cardiomyopathy.

Authors:  Paras Kumar Mishra; Srikanth Givvimani; Naira Metreveli; Suresh C Tyagi
Journal:  Biochem Biophys Res Commun       Date:  2010-09-15       Impact factor: 3.575

4.  Selenium restores defective beta-adrenergic receptor response of thoracic aorta in diabetic rats.

Authors:  Esma N Zeydanli; Ayca Bilginoglu; Evrim Tanriverdi; Hakan Gurdal; Belma Turan
Journal:  Mol Cell Biochem       Date:  2009-12-18       Impact factor: 3.396

5.  Zinc modulation of basal and β-adrenergically stimulated L-type Ca2+ current in rat ventricular cardiomyocytes: consequences in cardiac diseases.

Authors:  J Alvarez-Collazo; C M Díaz-García; A I López-Medina; G Vassort; J L Alvarez
Journal:  Pflugers Arch       Date:  2012-09-25       Impact factor: 3.657

6.  The contribution of reactive oxygen species and p38 mitogen-activated protein kinase to myofilament oxidation and progression of heart failure in rabbits.

Authors:  P Heusch; M Canton; S Aker; A van de Sand; I Konietzka; T Rassaf; S Menazza; O E Brodde; F Di Lisa; G Heusch; R Schulz
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 7.  Expression and Signaling of β-Adrenoceptor Subtypes in the Diabetic Heart.

Authors:  Betul R Erdogan; Martin C Michel; Ebru Arioglu-Inan
Journal:  Cells       Date:  2020-11-26       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.